Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020. The report details the vesting of Deferred Annual Bonus Plan (DABP) Mandatory and Matching Awards granted in 2017 to the Chief Executive Officer and other Persons Discharging Managerial Responsibilities (PDMRs). The performance period for these awards concluded on December 31, 2019.
Key Financial Metrics and Performance Outcomes
The vesting of the 2017 Matching Awards was determined by three performance measures over the three-year period ending December 31, 2019:
- Adjusted Free Cash Flow: The Company achieved £13 billion, exceeding the £12.95 billion target required for maximum vesting (100% of this portion vested).
- R&D New Products: New Product sales reached £7.254 billion, surpassing the £5.099 billion maximum vesting threshold (100% of this portion vested).
- Total Shareholder Return (TSR): GSK ranked 8th against a comparator group of 10 global pharmaceutical companies. This result fell below the threshold vesting level, resulting in 0% vesting for this portion.
Overall Vesting Result: 66.666% of the Matching Awards vested, while 33.334% lapsed.
Share Prices on Vesting Dates:
- Ordinary Shares (Feb 17, 2020): £16.616
- American Depositary Shares (ADSs) (Feb 18, 2020): $43.55
Material Changes and Transaction Details
The filing reports the release of shares to six PDMRs on February 17 and 18, 2020. These transactions represent the vesting of deferred bonus awards and the conditional matching awards. No cash consideration was paid by the executives for these shares (Price: £0.00/$0.00).
| Executive | Position | Instrument | Total Shares Released |
|---|---|---|---|
| Ms E Walmsley | Chief Executive Officer | Ordinary Shares | 62,036 |
| Mr R Connor | President, Global Vaccines | Ordinary Shares | 32,292 |
| Mr N Hirons | SVP, Global Ethics and Compliance | Ordinary Shares | 20,406 |
| Mr B McNamara | CEO, GSK Consumer Healthcare | ADSs | 11,861 |
| Mr D Redfern | Chief Strategy Officer | Ordinary Shares | 25,680 |
| Mr P Thomson | President, Global Affairs | Ordinary Shares | 12,171 |
Guidance, Outlook, and Risks
This filing does not contain forward-looking guidance, management commentary on future operations, or new risk factors. It is a regulatory notification regarding the settlement of historical equity awards based on performance metrics already finalized for the 2017-2019 period.
Key Facts for Investor Verification
- Verify the specific performance thresholds and vesting schedules for the 2017 DABP as disclosed in the 2018 Annual Report, as adjustments were noted.
- Confirm the composition of the "comparator group of 10 global pharmaceutical companies" used to calculate the Total Shareholder Return metric.
- Review the calculation methodology for "Adjusted Free Cash Flow" and "New Product sales" to ensure alignment with the principles stated in the filing.
- Note that the filing does not provide consolidated revenue, profit, or cash flow figures for the current reporting period; it only cites specific metric totals used for bonus vesting.